Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
13.12
-1.01 (-7.15%)
At close: Nov 20, 2024, 4:00 PM
13.04
-0.08 (-0.61%)
Pre-market: Nov 21, 2024, 7:19 AM EST

Intellia Therapeutics Revenue

Intellia Therapeutics had revenue of $9.11M in the quarter ending September 30, 2024, a decrease of -24.02%. This brings the company's revenue in the last twelve months to $43.09M, down -16.77% year-over-year. In the year 2023, Intellia Therapeutics had annual revenue of $36.28M, down -30.40%.

Revenue (ttm)
$43.09M
Revenue Growth
-16.77%
P/S Ratio
29.23
Revenue / Employee
$81,913
Employees
526
Market Cap
1.34B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202336.28M-15.85M-30.40%
Dec 31, 202252.12M19.07M57.69%
Dec 31, 202133.05M-24.94M-43.01%
Dec 31, 202057.99M14.89M34.55%
Dec 31, 201943.10M12.67M41.63%
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Dec 31, 2014 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
InMode 423.75M
BioCryst Pharmaceuticals 412.58M
Kiniksa Pharmaceuticals International, 384.10M
Travere Therapeutics 203.45M
Schrödinger 193.35M
Harrow 169.14M
Arvinas 161.10M
Ocular Therapeutix 61.44M
Revenue Rankings